---
layout: minimal-medicine
title: Luspatercept
---

# Luspatercept
### Generic Name
Luspatercept

### Usage

Luspatercept is a medication used to treat anemia (low red blood cell count) in specific adult populations.  Its primary use is in adults with beta-thalassemia who require regular red blood cell (RBC) transfusions.  It's also indicated for adults with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) whose anemia isn't responding to erythropoiesis-stimulating agents (ESAs) and who require two or more RBC units over eight weeks.  In essence, Luspatercept helps the body produce more red blood cells, thus reducing the need for transfusions in these specific patient groups. It is important to note that Luspatercept is not a substitute for immediate transfusion in cases requiring urgent correction of anemia.

### Dosage

Luspatercept is administered subcutaneously (under the skin).  Dosage varies based on the underlying condition and individual response.  The initial dose is generally 1 mg/kg every three weeks.  However, adjustments are frequently made based on hemoglobin levels and response to treatment.

**For beta-thalassemia:**

* **Initial dose:** 1 mg/kg every 3 weeks.
* **Dose escalation:** If there’s no reduction in RBC transfusion burden after at least two consecutive doses (6 weeks) at 1 mg/kg, the dose may be increased to 1.25 mg/kg every 3 weeks.  If there's still no improvement after three doses at 1.25 mg/kg, treatment should be discontinued.
* **Dose reduction:**  If the pre-dose hemoglobin level reaches ≥11.5 g/dL without transfusions, the dose should be interrupted and restarted only when the hemoglobin level drops to ≤11 g/dL.  If hemoglobin increases by >2 g/dL within 3 weeks without transfusions, dose reduction is necessary, potentially down to 0.6 mg/kg, with discontinuation if the increase persists at the lowest dose.

**For MDS-RS or MDS/MPN-RS-T:**

* **Initial dose:** 1 mg/kg every 3 weeks.
* **Dose escalation:**  Similar to beta-thalassemia, the dose may be increased to 1.33 mg/kg and then 1.75 mg/kg if there's no reduction in RBC transfusion burden. Treatment is discontinued if there's no response after three doses at 1.75 mg/kg.
* **Dose reduction:**  Similar criteria for dose reduction apply as with beta-thalassemia, based on pre-dose hemoglobin levels and rapid hemoglobin increases.

**Pediatric Use:** The safety and effectiveness of Luspatercept in children have not been established.

**Dosage Adjustments for Liver and Kidney Impairment:**  Generally, no dosage adjustments are needed for mild to moderate liver or kidney impairment, but  consult a healthcare professional for specific guidance in severe cases.


### Side Effects

Common side effects (>10%) may include: dizziness, fatigue, headache, vertigo, hypertension, abdominal pain, diarrhea, nausea, increased liver enzyme levels (ALT, AST, bilirubin), arthralgia (joint pain), musculoskeletal pain, and decreased creatinine clearance.

Less common but serious side effects (1-10% or less frequently reported) can include: thromboembolic events (blood clots), stroke, hyperuricemia, hypersensitivity reactions, and infections.

**Note:**  This is not an exhaustive list.  Any new or worsening symptoms should be reported to a healthcare provider immediately.

### How it Works

Luspatercept is a fusion protein that works by modifying the signaling pathways involved in red blood cell production.  It inhibits certain growth factors (TGF-beta superfamily ligands) that normally suppress red blood cell maturation. By reducing the inhibitory signals, Luspatercept allows for increased differentiation and proliferation of erythroid precursors (red blood cell stem cells), leading to increased red blood cell production and improved anemia.

### Precautions

* **Hypersensitivity:** Luspatercept is contraindicated in individuals with known hypersensitivity to it or its components.
* **Thromboembolic risk:**  There's an increased risk of thrombosis (blood clots) and thromboembolic events.  Patients with a history of blood clots or risk factors should be carefully monitored.
* **Hypertension:**  Luspatercept may elevate blood pressure. Regular blood pressure monitoring is necessary.
* **Bone pain and arthralgia:**  Joint and bone pain are potential side effects.
* **Pregnancy and breastfeeding:**  Luspatercept may harm a developing fetus.  Effective contraception is required for women of reproductive potential during treatment and for at least three months afterward. Breastfeeding is not recommended during treatment or for three months after the final dose.
* **Drug interactions:** While specific interactions are not extensively documented, informing your doctor about all other medications being taken is crucial.

### FAQs

* **Q: How long does it take to see results?**  A: The time to observe a clinical response varies, but improvements in hemoglobin levels and reduced transfusion requirements may be seen within several weeks of starting treatment.
* **Q: How is Luspatercept stored?** A: Refer to the product labeling for specific storage instructions. Generally, it's stored refrigerated.
* **Q: What should I do if I miss a dose?** A: Take the missed dose as soon as possible, but maintain the regular three-week dosing schedule.
* **Q: Are there any specific dietary restrictions?** A: There are no specific dietary restrictions associated with Luspatercept, but maintaining a healthy diet is always recommended.
* **Q: Can I drive while taking Luspatercept?** A: Dizziness and fatigue are possible side effects; assess your ability to drive safely before operating a vehicle.  Consult your healthcare professional for guidance.

**Disclaimer:** This information is intended for general knowledge and does not substitute professional medical advice. Always consult your doctor or pharmacist for personalized guidance on the use of Luspatercept and the management of your condition.  The information provided here is based on currently available data and may be subject to change. Always refer to the most updated prescribing information.
